Pfizer announced that the FDA has approved a prefilled dual-chamber syringe for administration of Xyntha (antihemophilic factor [recombinant]).

Labopharm and Angelini announced the launch of Oleptro (trazodone HCl extended-release tablets) for the treatment of major depressive disorder (MDD) in adults.

Sanofi-aventis announced that the FDA has approved a one-vial formulation of Taxotere (docetaxel injection concentrate).

Merz Pharmaceuticals announced that the FDA has approved Xeomin (incobotulinumtoxinA) for the treatment of adults with cervical dystonia to decrease the severity of abnormal head position and neck pain in both botulinum toxin-naïve and previously treated patients and blepharospasm in adults previously treated with onabotulinumtoxinA.

Sanofi Pasteur announced that it has begun shipping the 2010-2011 formulation of Fluzone (trivalent inactivated "split virus" influenza vaccine [Types A and B]).

GlaxoSmithKline announced that it has begun shipping the 2010-2011 formulation of FluLaval (trivalent, inactivated, "split virus" influenza vaccine [Types A and B]) and anticipates distributing Fluarix (trivalent, inactivated, "split virus" influenza vaccine [Types A and B]) in the next several weeks.

Abbott announced that it has received FDA approval for two new dosage strengths of Simcor (niacin extended-release/simvastatin tablets).

The FDA has approved Cuvposa (glycopyrrolate liquid, from Shionogi), an orphan drug, for the treatment of chronic severe drooling associated with neurologic conditions (eg, cerebral palsy) in patients 3-16 years of age.

MedImmune announced that it has begun shipping FluMist (intranasal, live, attenuated influenza vaccine) to vaccine distributors who service healthcare providers.

The FDA has approved Finesse, an insulin patch-pen from Calibra Medical, for up to three-day use with Novolog (insulin aspart, from Novo Nordisk).